Integrated Network Pharmacology, Single‐Cell Transcriptomics Unveil the Mechanistic Role of Morusin in Aortic Dissection

Zhaomeng Wang, Haoran Zhang, Zhanxiong Xie, Yukun Xiang, Yiwen Fu, Haiqing Jiao, Nan Lin, Chenguang Niu, Chao Jiang, Jian KongJournal of Cellular and Molecular Medicine 2026 · DOI

TL;DR

This study leverages a multi-omics approach, combining network pharmacology, molecular docking, and single-cell transcriptomics, to uncover the therapeutic potential of morusin, a natural flavonoid, in treating aortic dissection (AD). The findings reveal that morusin acts through multiple targets and pathways, notably the IL-17, HIF-1, and MAPK signaling pathways, to mitigate AD progression, suggesting its promise as a multi-target therapeutic candidate.

What Problem Does This Paper Address?

Aortic dissection (AD) is a critical cardiovascular emergency with a high mortality rate and limited effective pharmacological treatments. Current management primarily relies on surgical interventions or supportive care, with a significant unmet need for drugs that directly address the underlying pathological mechanisms. AD is characterized by the tearing of the aortic intima, leading to a false lumen and potentially catastrophic outcomes like rupture or ischemia. Key drivers of AD include hypertension, connective tissue disorders, and inflammation, but specific therapeutic agents targeting these complex processes are lacking. This paper aims to fill this gap by investigating the potential of morusin, a natural compound with known anti-inflammatory and antioxidant properties, to combat AD.

Methods

The researchers employed a comprehensive, multi-faceted approach:

  • Network Pharmacology: This systems-level strategy was used to identify potential drug targets and disease-related genes. They integrated data from multiple public databases (TargetNet, PharmMapper, SuperPred, SwissTargetPrediction) to identify morusin's targets and searched the GeneCards database for AD-related genes. The overlap between these two sets yielded potential therapeutic targets for morusin in AD.
  • Pathway Enrichment Analysis: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed on the identified targets to understand the biological processes, molecular functions, and signaling pathways involved.
  • Protein-Protein Interaction (PPI) Network Construction: The STRING database was used to build a PPI network of the core targets, and topological analysis (degree centrality, betweenness centrality, closeness centrality) was performed using Cytoscape and CytoNCA to identify key regulatory nodes (hub genes).
  • Molecular Docking: This technique was used to computationally predict the binding affinity and stability of morusin with the identified key target proteins. AutoDock Vina was employed for the docking simulations.
  • Single-Cell RNA Sequencing (scRNA-seq): Publicly available scRNA-seq data from human AD tissues (GSE213740) was analyzed to understand the cell-type-specific expression patterns of the identified hub target genes. This allowed for a granular view of how different cell types in the aortic tissue are affected.
  • Experimental Validation:
    • In vitro: Human aortic vascular smooth muscle cells (HAVSMCs) were used to create an inflammatory model by stimulating them with Angiotensin II (AngII). The effects of morusin on cell viability and the expression of key pathway-related genes (via qRT-PCR) were then assessed.
  • In vivo: An AD mouse model was established using β-aminopropionitrile (BAPN) administration. The therapeutic efficacy of morusin was evaluated by measuring aortic dilation (via ultrasonography), dissection incidence, mortality, and performing histological analysis of aortic tissues.

Datasets

  • Morusin Target Databases: PharmMapper, SuperPred, TargetNet, SwissTargetPrediction.
  • Aortic Dissection (AD) Related Genes Database: GeneCards.
  • Single-Cell RNA Sequencing Data: NCBI Gene Expression Omnibus (GEO) accession number GSE213740 (human aortic dissection tissues).
  • Protein Data Bank (PDB): Used for retrieving 3D structures of target proteins for molecular docking.

No new benchmarks were introduced; the study utilized existing databases and established experimental models.

Key Insights and Ideas

  • Polypharmacology of Morusin: The study strongly supports the idea that morusin exerts its effects not through a single target but by modulating multiple molecular targets and pathways simultaneously, a characteristic of many natural products.
  • IL-17 Pathway as a Central Player: The IL-17 signaling pathway emerged as a critical hub in morusin's mechanism of action against AD, highlighting its role in the inflammatory cascade of the disease.
  • Cell-Type Specificity in AD: Single-cell transcriptomics revealed that key target genes are dysregulated in specific cell types within the AD tissue, particularly the upregulation of MAPK8 in fibroblasts and immune cells, offering a more nuanced understanding of AD pathology.
  • Morusin's Dual Action: Morusin appears to mitigate AD by targeting both inflammatory processes (e.g., modulating MAPK8) and potentially cell death pathways (e.g., influencing CASP3 expression), suggesting a broad protective effect.

Key Results

  • Target Identification: 281 morusin targets and 1741 AD-related genes were identified, with 84 overlapping targets.
  • Key Pathways: Enrichment analyses highlighted IL-17, HIF-1, and MAPK signaling pathways as significantly involved.
  • Hub Genes: Seven key targets (HSP90AA1, MAPK8, MAPK1, MAPK14, PTGS2, NFKB1, and CASP3) were identified as crucial, all showing high binding affinity to morusin in molecular docking simulations (binding energies ranging from -9.0 to -7.0 kcal/mol).
  • scRNA-seq Findings: MAPK8, MAPK1, PTGS2, and MAPK14 were significantly upregulated in fibroblasts, B cells, and T cells from AD tissues. HSP90AA1 was downregulated in T and B cells.
  • In Vitro Efficacy: Morusin dose-dependently inhibited AngII-induced HAVSMC proliferation, achieving over 80% suppression at 9 µg/mL. It also modulated IL-17 pathway gene expression.
  • In Vivo Efficacy: Morusin treatment significantly attenuated aortic dilation, reduced dissection incidence (46% vs. 69% in vehicle), and decreased mortality (8% vs. 23% in vehicle) in a BAPN-induced AD mouse model. Histopathology confirmed preserved vascular integrity.

Limitations and Future Work

  • Limitations:
    • The study acknowledges that future research should further validate these target regulatory effects in an Apoe-/- mouse model of AD, which is a more established model for atherosclerosis and vascular disease.
  • The authors suggest employing conditional gene knockout models to dissect the specific roles of these targets in distinct cell types, which would provide more definitive mechanistic insights.
  • Future Work:
    • The authors propose that future studies should aim to directly evaluate morusin's capacity to regulate endothelial vWF expression and ET-1 secretion, as these pathways are implicated in AngII-induced endothelial dysfunction and AD.
  • Further investigation into the balance between pyroptosis and apoptosis modulated by morusin, particularly concerning CASP3, is suggested.
  • The study highlights the need for further validation of morusin's therapeutic potential in more complex AD models and potentially in clinical trials.

Summary updated

Abstract

Aortic dissection is a life-threatening cardiovascular emergency with limited pharmacological options. This study focuses on elucidating the multi-target and multi-pathway mechanisms through which morusin mitigates aortic dissection progression, integrating network pharmacology, single-cell transcriptomics and experimental validation. Multi-database analysis identified 281 morusin targets and 1741 ad-related genes, with 84 overlaps. Enrichment analyses highlighted IL-17, HIF-1 and MAPK signalling pathways as potential regulatory hubs. Protein-protein interaction network analysis identified seven key targets, all showing high binding affinity to morusin in molecular docking. Single-cell transcriptomics revealed cell-type-specific dysregulation, notably MAPK8 upregulation in fibroblasts and immune cells. In vitro, morusin dose-dependently inhibited AngII-induced vascular smooth muscle cell proliferation and modulated IL-17 pathway gene expression. In vivo, morusin attenuated aortic dilation and reduced morbidity and mortality in a BAPN-induced AD mouse model. These findings suggest that morusin mitigates AD progression by targeting key inflammatory and apoptotic pathways, supporting its potential as a multi-target therapeutic candidate.
BibTeX
@article{wang2026integrated,
  author = {Zhaomeng Wang and Haoran Zhang and Zhanxiong Xie and Yukun Xiang and Yiwen Fu and Z Q Wang and Haiqing Jiao and Nan Lin and Chenguang Niu and Chao Jiang and Jian Kong},
  title = {{Integrated Network Pharmacology, Single‐Cell Transcriptomics Unveil the Mechanistic Role of Morusin in Aortic Dissection}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  doi = {10.1111/jcmm.70971},
}
Figure